肿瘤领域激酶抑制剂的治疗药物监测
本文综述了截至2023年7月1日FDA/EMA批准的77种激酶抑制剂的治疗药物监测证据,阐述了暴露-效应与暴露-毒性关系,并尽可能提供TDM实用建议和药代动力学目标。
要点
- 激酶抑制剂存在较大个体间变异,固定剂量可能导致毒性或疗效不足。
- 已有多种激酶抑制剂建立了暴露-效应和暴露-毒性关系。
- 基于血药浓度调整剂量(TDM)可改善疗效并减少毒性。
核心结论
- TDM可用于优化激酶抑制剂的疗效并降低毒性发生率。
研究设计与样本
- 对截至2023年7月1日FDA/EMA批准的77种用于血液和肿瘤的激酶抑制剂进行综合性综述。
主要发现
- 多种激酶抑制剂已建立暴露-效应和暴露-毒性关系。
- 固定剂量方案可能导致不必要的毒性和次优疗效。
关键数值与推荐
- 原文未提供具体药代动力学目标数值。
临床怎么用
- 基于测定的系统药代动力学水平进行剂量调整(即TDM)以改善治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Although kinase inhibitors (KI) frequently portray large interpatient variability, a 'one size fits all' regimen is still often used. In the meantime, relationships between exposure-response and exposure-toxicity have been established for several KIs, so this regimen could lead to unnecessary toxicity and suboptimal efficacy. Dose adjustments based on measured systemic pharmacokinetic levels-i.e., therapeutic drug monitoring (TDM)-could therefore improve treatment efficacy and reduce the incidence of toxicities. Therefore, the aim of this comprehensive review is to give an overview of the available evidence for TDM for the 77 FDA/EMA kinase inhibitors currently approved (as of July 1st, 2023) used in hematology and oncology. We elaborate on exposure-response and exposure-toxicity relationships for these kinase inhibitors and provide practical recommendations for TDM and discuss corresponding pharmacokinetic targets when possible.
引用
- van der Kleij MBA, Guchelaar NAD, Mathijssen RHJ, et al. Therapeutic Drug Monitoring of Kinase Inhibitors in Oncology. Clin Pharmacokinet. 2023. PMID: 37584840. doi:10.1007/s40262-023-01293-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。